New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
06:22 EDTHZNP, ESRX, CVSHorizon Pharma said Duexis, Vimovo to be placed on CVS, Express exlclusion lists
Horizon Pharma (HZNP) said it has been verbally notified that in August, two pharmacy benefit managers, CVS Caremark (CVS) and Express Scripts (ESRX), expect to announce DUEXIS and VIMOVO will no longer be on their formularies and will be placed on their exclusion lists effective January 1, 2015. As a change in Caremark and ESI formulary status would not take effect until 2015, Horizon Pharma does not expect this potential action to impact the financial guidance of $270M-280M for net revenues and $80M-90M for adjusted EBITDA for fiscal 2014 as provided in first quarter earnings press release dated May 9. In response to potentially being placed on Caremarkís and ESIís exclusion lists, the company said it will immediately accelerate patient and physician focused commercial model to focus prescriptions through other channels such as our Prescriptions Made Easy program, continue working with many of the other PBMs and evaluate price increases. We estimate approximately 20%-30% of DUEXIS and VIMOVO prescriptions could be impacted by the potential actions by Caremark and ESI. In the future, if additional healthcare plans adopt the Caremark or ESI exclusion lists or otherwise exclude DUEXIS or VIMOVO from the formularies they use, which they are not required to do, there could possibly be additional DUEXIS and VIMOVO prescriptions affected.
News For HZNP;CVS;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
07:45 EDTHZNPHorizon Pharma price target raised to $27 from $18 at Brean Capital
Subscribe for More Information
February 27, 2015
14:38 EDTHZNPHorizon Pharma price target raised to $30 from $24 at Avondale
09:24 EDTHZNPOn The Fly: Pre-market Movers
Subscribe for More Information
07:12 EDTHZNPHorizon Pharma raises FY15 revenue guidance to $450M-$475M from $425M-$450M
Subscribe for More Information
07:10 EDTHZNPHorizon Pharma reports Q4 adjusted EPS 27c, consensus 22c
Reports Q4 revenue $103.8M, consensus $95.54M.
February 26, 2015
07:36 EDTESRXExpress Scripts price target raised to $90 from $85 at Leerink
Subscribe for More Information
February 25, 2015
10:11 EDTESRXExpress Scripts says willing to do 'tranformational' deal
Subscribe for More Information
February 24, 2015
13:23 EDTESRX, CVSLeerink healthcare technology analyst holds analyst/industry conference call
Healthcare Tech & Distribution Analyst Larsen discusses th 2016 Pharmacy Benefits Management (PBM) selling season, the impact of the Hep C PBM formulary negotiations on the selling season and specialty drug trend and areas of opportunity for PBMs on an Analyst/Industry conference call to be held on March 5 at 2 pm.
February 23, 2015
18:02 EDTESRXOn The Fly: After Hours Movers
Subscribe for More Information
16:04 EDTESRXExpress Scripts sees Q1 EPS $1.07-$1.11, consensus $1.16
Subscribe for More Information
16:03 EDTESRXExpress Scripts sees FY15 EPS $5.35-$5.49, consensus $5.44
Subscribe for More Information
16:02 EDTESRXExpress Scripts reports Q4 EPS 1.39, consensus $1.38
Subscribe for More Information
15:23 EDTESRXNotable companies reporting after market close
Subscribe for More Information
06:28 EDTESRXExpress Scripts weekly volatility elevated into Q4 and outlook
Subscribe for More Information
February 20, 2015
10:20 EDTHZNPHigh option volume stocks
Subscribe for More Information
07:08 EDTHZNPAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 18, 2015
05:36 EDTESRXExpress Scripts to host investor meeting
Investor meeting to be held in St. Louis on February 25 at 8:30 am. Webcast Link
February 17, 2015
17:29 EDTESRXBerkshire Hathaway gives quarterly update on stakes, exits Exxon Mobil
Subscribe for More Information
10:01 EDTCVSCVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use